Drug Type Small molecule drug |
Synonyms Simotinib, Ximotini, AL-6802 + [1] |
Target |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
RegulationSpecial Review Project (CN) |
Molecular FormulaC25H27Cl2FN4O4 |
InChIKeyRNEAUPHMDFWZDA-UHFFFAOYSA-N |
CAS Registry1538617-88-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-Small Cell Lung Cancer | Phase 1 | CN | 15 Apr 2013 | |
Breast Cancer | Phase 1 | CN | - | |
Breast Cancer | Phase 1 | - | - | |
Colonic Cancer | Phase 1 | CN | - | |
Colonic Cancer | Phase 1 | - | - |
Phase 1 | EGFR-mutated non-small Cell Lung Cancer EGFR Mutation | 41 | ydefihwdpi(xwkkwehgsm) = kskgfactua tnztuoaakc (zrxfavvczp ) View more | Positive | 13 May 2019 | ||
Phase 1 | Advanced Lung Non-Small Cell Carcinoma First line | 41 | ougqzrwtkg(nqorynmtev) = Simotinib was well tolerated, with encouraging efficacy observed in NSCLC patients with EGFR sensitive mutations, particularly in those with BM pexqgwewzz (zlsrysjtiq ) | - | 30 May 2017 |